Multiple nucleic acid and nucleotide metabolism targets

The term Multiple nucleic acid and nucleotide metabolism targets refers to a broad category of enzymes and regulatory proteins essential for the biosynthesis, salvage, and maintenance of purine and pyrimidine nucleotides (StatPearls: Antimetabolites, 2023). These targets, including dihydrofolate reductase (DHFR), thymidylate synthase (TS), and ribonucleotide reductase (RNR), are fundamental to DNA replication and RNA transcription, making them primary focal points for anti-proliferative therapies. Drugs targeting these pathways, collectively known as antimetabolites, are widely used in the treatment of various malignancies and autoimmune disorders by mimicking natural metabolites and inhibiting key enzymatic steps (NCI Dictionary: Antimetabolite). By disrupting the availability of nucleotide building blocks, these agents induce cell cycle arrest and programmed cell death in rapidly dividing cells. However, the lack of absolute specificity for cancerous versus healthy proliferating cells often results in significant clinical toxicities, such as bone marrow suppression and damage to the gastrointestinal mucosa (ACS: How Antimetabolites Work). Precision medicine approaches now utilize pharmacogenetic biomarkers to optimize dosing and minimize adverse effects for drugs hitting these targets. Overall, this group of targets remains a cornerstone of cytotoxic chemotherapy and immunosuppressive regimens.

Other names

Nucleotide metabolism enzymesAntimetabolite targetsPurine and pyrimidine synthesis pathwaysNucleic acid synthesis targets

Inhibition of multiple enzymes within the purine and pyrimidine biosynthetic pathways, resulting in the depletion of nucleotide pools and the cessation of nucleic acid synthesis (StatPearls: Antimetabolites, 2023).